Suppression of T-cell activation by administration of MHC class II-binding peptides

Protective effect of UDCA against IL-11- induced cardiac fibrosis is mediated by TGR5 signalling.

Frontiers in cardiovascular medicine·2024

Farnesoid X receptor activation by the novel agonist TC-100 (3α, 7α, 11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid) preserves the intestinal barrier integrity and promotes intestinal microbial reshaping in a mouse model of obstructed bile acid flow.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2022

The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma.

PloS one·2019

Therapeutic effects of the selective farnesoid X receptor agonist obeticholic acid in a monocrotaline-induced pulmonary hypertension rat model.

Journal of endocrinological investigation·2019

Therapeutic effects of obeticholic acid (OCA) treatment in a bleomycin-induced pulmonary fibrosis rat model.

Journal of endocrinological investigation·2018

Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression.

Biochimica et biophysica acta. Molecular basis of disease·2017

Lentivirus infection of macrophages.

Immunology series·1994

The macrophage and HIV-1.

Immunology series·1994

Macrophage-Cryptococcus interactions.

Immunology series·1994

Macrophage interactions with Candida.

Immunology series·1994

Macrophages in experimental Chagas' disease.

Immunology series·1994

Macrophages and Brucella.

Immunology series·1994

Budesonide in Liver Transplant Recipients requiring Long-term Corticosteroid in Maintenance Immunosuppression: A Retrospective Case Series.

Transplantation proceedings·2026

Surgical protocol and ischemic duration determine myeloid cell features and locomotor deficits in preclinical transient middle cerebral artery occlusion.

Experimental neurology·2026

Safety and antitumor activity of the first-in-class EGFR-HER3 bispecific antibody-drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase 1b study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Uncovering combination therapies for immune-mediated inflammatory diseases through systems biology analysis on longitudinal patient data.

Cell reports. Medicine·2026

Interleukin-10 in endometriosis: a systematic review of systemic and local immune compartment differences.

European journal of obstetrics, gynecology, and reproductive biology·2026

CBL0137 inhibits TFR2-mediated IgA1 deposition in IgA nephropathy.

International immunopharmacology·2026

Related Experiment Videos

Suppression of T-cell activation by administration of MHC class II-binding peptides

Related Concept Videos

Protective effect of UDCA against IL-11- induced cardiac fibrosis is mediated by TGR5 signalling.

Farnesoid X receptor activation by the novel agonist TC-100 (3α, 7α, 11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid) preserves the intestinal barrier integrity and promotes intestinal microbial reshaping in a mouse model of obstructed bile acid flow.

The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma.

Therapeutic effects of the selective farnesoid X receptor agonist obeticholic acid in a monocrotaline-induced pulmonary hypertension rat model.

Therapeutic effects of obeticholic acid (OCA) treatment in a bleomycin-induced pulmonary fibrosis rat model.

Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression.

Lentivirus infection of macrophages.

The macrophage and HIV-1.

Macrophage-Cryptococcus interactions.

Macrophage interactions with Candida.

Macrophages in experimental Chagas' disease.

Macrophages and Brucella.

Budesonide in Liver Transplant Recipients requiring Long-term Corticosteroid in Maintenance Immunosuppression: A Retrospective Case Series.

Surgical protocol and ischemic duration determine myeloid cell features and locomotor deficits in preclinical transient middle cerebral artery occlusion.

Safety and antitumor activity of the first-in-class EGFR-HER3 bispecific antibody-drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase 1b study.

Uncovering combination therapies for immune-mediated inflammatory diseases through systems biology analysis on longitudinal patient data.

Interleukin-10 in endometriosis: a systematic review of systemic and local immune compartment differences.

CBL0137 inhibits TFR2-mediated IgA1 deposition in IgA nephropathy.

Related Experiment Videos

Suppression of T-cell activation by administration of MHC class II-binding peptides

Related Concept Videos

Related Articles